Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas.

Front Immunol · 2023 · PMC10083339 · PMID 37051246

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

marginal significanceP= 0.055so close (0.05 < p ≤ 0.1)

At the 1-year follow-up, the EFS rates in the CAR-T[early] group and CAR-T[late] group were 48% and 30%, respectively, with marginal significance (P= 0.055), and similarly, the OS rates were 75% vs. 56% in favor of the CAR-T[early] group (P = 0.053) ( 79 ).

also in 3,088 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.